Learn About NETs and monthly meetings

Posted by Teresa, Volunteer Mentor @hopeful33250, Nov 15, 2021

There are many opportunities to learn more about this very elusive and hard-to-diagnose disorder called Neuroendocrine Tumors (NETs)/Carcinoids. When a new learning opportunity becomes available it will be posted here.

Interested in more discussions like this? Go to the Neuroendocrine Tumors (NETs) Support Group.

mfgw | @mfgw | Dec 8, 2021

Good Afternoon,
I personally have been diagnosed with cancer. I have carcinoid and NETs, Stage 2. I start Octreotide tomorrow. My care team are all a part of University Health and UT Health in San Antonio, TX.

Teresa, Volunteer Mentor | @hopeful33250 | Dec 8, 2021

Hello @mfgw,

I appreciate your correction to the date. I also see that this is your first post on Mayo Clinic Connect, welcome!

I would be interested in knowing something about your interest in Carcinoid Cancer. Have you or a family member recently had this diagnosis?

Teresa, Volunteer Mentor | @hopeful33250 | Dec 7, 2021

On Thursday, December 9, the Carcinoid Cancer Foundation, will be hosting a Facebook Live program with Dr. Dasari. Dr. Dasari has a clinical focus on neuroendocrine cancer and he currently serves as Co-Chair of the MD Anderson multidisciplinary neuroendocrine tumor board.

There will be a time to post questions during this Facebook Live webinar. If you are interested in attending, click on this link,
https://www.carcinoid.org/2021/12/05/dr-n-arvind-dasari-to-be-featured-guest-for-ccfs-luncheon-with-the-experts/

Teresa, Volunteer Mentor | @hopeful33250 | Nov 15, 2021

Thursday, November 18, from 12 noon until 1 p.m. EST. Dr. Chandrasekharan, an oncologist from the University of Iowa, will be speaking at a FaceBook Live Meeting. Information on how to join this meeting is provided in the link below.
https://www.carcinoid.org/2021/11/14/dr-chandrikha-chandrasekharan-to-be-featured-guest-for-ccfs-luncheon-with-the-experts/
As you read the link you will see that there are opportunities to submit questions.